Industry news

Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

Lisa Urquhart / BioTechNow

The pharmaceutical industry continues its impressive two-year growth with no signs of slowing down according to new consensus forecast data from the annual state of the industry report, “World Preview 2015, Outlook to 2020” from market intelligence firm, Evaluate. The report, which launched today at the 2015 BIO International Convention, found that worldwide prescription drug sales are expected to grow at 4.8 percent a year until 2020 – growth that is being fueled by the US which saw an 8.9 percent jump in sales in 2014.

Big Pharma (and Big Biotechs) riding drug approval surge toward $1T in sales

Eric Palmer / FeircePharma

The FDA approved a record 50 new drugs last year and 6 of those, coming from 6 different companies, are forecast to reach blockbuster sales in 2019.

New study will test feds' support for anti-aging drug research

John Carroll / FierceBiotech

Investigators will be making the trek to Washington later this month to make the case for a new study that will explore the impact that metformin has on aging. And in the process, they'll be testing regulators' attitudes about an emerging field in drug development.

Moscow scientists develop new early-stage diagnostics for cancer, HIV and more

MarchMont Innovation News

Dmitry Fedyanin and Yuri Stebunov, two young scientists from the Nanophotonics and Plasmonics Lab at MIPT, a leading Russian university in Moscow, have developed what they call a nanomechanical sensor to identify chemical components of various substances, the MIPT website  announced . 
 

Turkey Expands Reach in Pharma Market

BioPharm International

The first day of CPhI Istanbul (June 3–5, 2015), UBM EMEA announced its findings of the Pharma Insights Turkey Market Report 2015. The report, which is part of a longer report available from CPhI Istanbul titledTurkish Pharmaceuticals 2015: Turkey, Research & Development and Regional Growth, was compiled with the help of Global Business Reports. 

Russia masterminds its International Medical Cluster — for now only for Moscow

MarchMont Innovation News

The State Duma, the lower house of Russian Parliament, passed a draft bill on the development of an “International Medical Cluster” in Russia. The stated goals of the new effort include further medical development, transfer of advanced technologies into Russia, and the providing of high-quality medical assistance for populations. 

Moscow and Australian scientists improve lives with ultra-resilience

MarchMont Innovation News

A consortium of Prof. Sergei Prokoshkin led group of Russian scientists at MISiS, a leading Russian university based in Moscow, and experts from Endogene-Globetek, an Australian company, has tapped into the physical effect of shape-memory and ultra-resilience alloys to develop innovation technologies, the MISiS website  announced . 

17 June 2015

Celtaxsys $40.00 million Fundraising. William P Reddick Submitted Jun 10 SEC Form

Octafinance.com

Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

So A New Drug Takes $1 Billion?

Louis Garguilo / Outsourced Pharma

First, let’s consider toning down the billion-dollar baying; it’s become a confused expression of sardonic triumph: “Well, they say it takes a billion dollars to get a new drug nowadays! Harrumph!”

Branded pharma worries, generics makers cheer as trade pact hits snag in Congress

Tracy Staton / Fierce Pharma

The Trans-Pacific Partnership took it on the chin Friday when the U.S. House voted against a key assistance program for workers displaced by global trade. That move throws a wrench into U.S. efforts to pass the controversial trade agreement, which pharma companies have lobbied hard to shape.